| 000 | 03130nlm1a2200445 4500 | ||
|---|---|---|---|
| 001 | 651337 | ||
| 005 | 20231030041030.0 | ||
| 035 | _a(RuTPU)RU\TPU\network\16586 | ||
| 035 | _aRU\TPU\network\16462 | ||
| 090 | _a651337 | ||
| 100 | _a20161109a2016 k y0engy50 ba | ||
| 101 | 0 | _aeng | |
| 135 | _adrcn ---uucaa | ||
| 181 | 0 | _ai | |
| 182 | 0 | _ab | |
| 200 | 1 |
_aNeuroprotective effects of p-tyrosol after the global cerebral ischemia in rats _fD. N. Atochin [et al.] |
|
| 203 |
_aText _celectronic |
||
| 300 | _aTitle screen | ||
| 320 | _a[References: p. 791-792 (36 tit.)] | ||
| 330 | _aBackground. Salidroside is a biologically active compound derived from Rhodiola rosea L. Studies showed that salidroside after i.v. injection is extensively metabolized to p-tyrosol and only trace amounts of salidroside are found in the brain tissue.Objective. The aim of the study was to investigate the neuroprotective effects of p-tyrosol in the global cerebral ischemia-reperfusion (GCI) model.Study design. A total of 103 Wistar rats were assigned to groups of sham-operated (n = 10), control (n = 42), p-tyrosol-treated (n = 36), and pentoxifylline-treated (n = 15) animals. The rats of control, p-tyrosol-treated, and pentoxifylline-treated groups received intravenously 0.9% NaCl solution, 2% solution of p-tyrosol in doses of 5 mg/kg, 10 mg/kg, and 20 mg/kg, and pentoxifylline in a dose of 100 mg/kg, respectively, daily for 5 days. Rats were examined at days 1, 3, and 5 after GCI. After evaluation of neurological deficit, animals were euthanized for morphological and biochemical characterization. | ||
| 333 | _aРежим доступа: по договору с организацией-держателем ресурса | ||
| 461 | _tPhytomedicine | ||
| 463 |
_tVol. 23, iss. 7 _v[P. 784–792] _d2016 |
||
| 610 | 1 | _aэлектронный ресурс | |
| 610 | 1 | _aтруды учёных ТПУ | |
| 701 | 1 |
_aAtochin _bD. N. _cneuroscientist _cThe Head of the Laboratory of Tomsk Polytechnic University _f1960- _gDmitry Nikolaevich _2stltpush _3(RuTPU)RU\TPU\pers\37514 |
|
| 701 | 1 |
_aChernysheva _bG. A. |
|
| 701 | 1 |
_aSmolyakova _bV. I. |
|
| 701 | 1 |
_aOsipenko _bA. N. |
|
| 701 | 1 |
_aLogvinov S. V. _bS. V. |
|
| 701 | 1 |
_aZhdankina _bA. A. |
|
| 701 | 1 |
_aSysolyatin _bS. V. |
|
| 701 | 1 |
_aKryukov _bYu. A. |
|
| 701 | 1 |
_aAnfinogenova _bYa. J. _cLinguist _cLecturer of Tomsk Polytechnic University, Doctor of medical sciences _f1970- _gYana Jonovna _2stltpush _3(RuTPU)RU\TPU\pers\33592 |
|
| 701 | 1 |
_aPlotnikova _bT. M. |
|
| 701 | 1 |
_aPlotnikov _bM. B. |
|
| 712 | 0 | 2 |
_aНациональный исследовательский Томский политехнический университет (ТПУ) _bУправление проректора по научной работе и инновациям (НРиИ) _bЦентр RASA в Томске (Центр RASA) _bЛаборатория изучения механизмов нейропротекции (Лаб. ИМН) _h7608 _2stltpush _3(RuTPU)RU\TPU\col\21815 |
| 801 | 2 |
_aRU _b63413507 _c20161109 _gRCR |
|
| 856 | 4 | _uhttp://dx.doi.org/10.1016/j.phymed.2016.03.015 | |
| 942 | _cCF | ||